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Background. Bacterial skin and skin structure infections (SSSIs) are frequent settings for 24 
antibiotic use.  We surveyed their UK aetiology and pathogen susceptibility, including to 25 
ceftaroline.  Materials and Methods.  Consecutive SSSI isolates were collected at 35 UK 26 
hospitals, to a maximum of 60/site, together with 15 ‘supplementary’ MRSA/site. Isolates 27 
were re-identified and BSAC susceptibility testing performed, with parallel CLSI agar testing 28 
for ceftaroline.  Results. Isolates (n=1908) were collected from 1756 hospitalised patients, 29 
predominantly with surgical and traumatic infections, abscesses and infected ulcers and 30 
primarily from General Medicine and General Surgery.  They included 1271 Staphylococcus 31 
aureus (201 MRSA), 162 -haemolytic streptococci, 269 Enterobacteriaceae, 138 32 
Pseudomonas aeruginosa and 37 enterococci. Most (944/1756) patients had monomicrobial 33 
MSSA infections. Resistance rates to quinolones, gentamicin and cephalosporins were 34 
<20% in Enterobacteriaceae and <10% in P. aeruginosa. MRSA rates varied greatly among 35 
hospitals and were 2.5-fold higher in General Medicine than General Surgery.  At breakpoint, 36 
ceftaroline inhibited (i) all MSSA and 97.6% of MRSA, with MICs of 2 mg/L for the few 37 
resistant MRSA, (ii) all -haemolytic streptococci and (iii) 83% of Enterobacteriaceae. High-38 
level ceftaroline resistance in Enterobacteriaceae involved ESBLs and AmpC enzyme. 39 
Ceftaroline MICs by CLSI methodology generally equalled those by BSAC or were two-fold 40 
higher, but this differential was 4-16-fold for P. aeruginosa. Conclusion.  Irrespective of 41 
patient group, SSSIs were dominated by S. aureus.  Most pathogens were susceptible; but 42 
15.8% of S. aureus were MRSA, with locally higher prevalence.   43 
44 
Introduction 45 
Skin and skin structure infections (SSSIs, or ‘Acute Bacterial Skin and Skin Structure 46 
Infections’ or ABSSSI in FDA terminology1) range from trivial to the life threatening. They are 47 
important in both hospitals and the community, with categorisation complicated by the fact 48 
that hospital acquired (e.g. post-surgical) SSSIs increasingly manifest in the community, 49 
following early hospital discharge.2   Regulatory agencies divide SSSIs as ‘complicated’ or 50 
‘uncomplicated’ according to the depth of the structures involved, but routine practice mostly 51 
categorised by type (cellulitis, surgical site etc.).  SSSI aetiology is dominated by 52 
Staphylococcus aureus but other common isolates include -haemolytic streptococci, 53 
enterococci, Enterobacteriaceae, anaerobes and Pseudomonas aeruginosa.3 In a mixed 54 
flora, it is often difficult to distinguish pathogens and secondary colonists with confidence. 55 
 There is great variation in SSSI treatment, with 54 antibiotic regimens represented 56 
among 1995 SSSI patients at 129 hospitals.4  Severity varies hugely too, with UK evidence 57 
suggesting that severe SSSIs are frequently undertreated, sometimes with adverse 58 
consequences, whereas mild infections are often over-treated.5 Guiding principles are that 59 
the regimen should reflect: (i) the likelihood of a mixed flora, including gram-negatives; (ii) 60 
the prevalence of MRSA and (iii), severity, along with the consequences of failure.  The 61 
prevalence of MRSA among bloodstream infections in the UK has been substantially 62 
reduced, but their residual prevalence in SSSIs is less clear.   Multiple antibiotics – 63 
ceftaroline, dalbavancin, daptomycin, linezolid, oritavancin, quinupristin-dalfopristin, 64 
tedizolid, and tigecycline – have been licensed for SSSIs since the turn of the century, all 65 
with anti-MRSA activity.6  Most only act against gram-positive pathogens but ceftaroline and 66 
tigecycline, also inhibit Enterobacteriaceae, but not P. aeruginosa. 67 
 We surveyed the current aetiology of SSSIs among hospitalised patients in the UK, 68 
considering MRSA prevalence in particular. In addition we ascertained (i) the coverage 69 
offered by ceftaroline and (ii) the extent to which the MIC distribution for MRSA is cut by 70 
EUCAST's 1 mg/L breakpoint (http://www.eucast.org).  71 
 Materials and methods 72 
SSSI survey 73 
We recruited 40 UK laboratories, asking each to collect 60 consecutive clinically-significant 74 
isolates from hospitalised patients with SSSI and to send these to Public Health England’s 75 
Antimicrobial Resistance and Healthcare Associated Infections Reference Unit (AMRHAI). 76 
Collection ran from August 2012 to December 2013, and 35 sites contributed isolates (See 77 
Acknowledgements); 29 were in England, three in Scotland, two in Wales and one in 78 
Northern Ireland.  Bacteria sought included S. aureus, β-haemolytic streptococci, 79 
enterococci, Enterobacteriaceae or non-fermenters. Anaerobes were excluded, as were: (i) 80 
commensal species likely to be contaminants, including coagulase-negative staphylococci, 81 
micrococci, propionibacteria and coryneforms, (ii) -haemolytic staphylococci and (iii) 82 
category III pathogens. Only one isolate per species per patient was permitted, except that 83 
MRSA and MSSA could be included.  A case record form was sought for each isolate, 84 
collecting demographic and clinical data.    85 
 To expand the MRSA collection we also asked laboratories to submit a further 15 86 
MRSA from SSSIs subsequent to their collection of 60 consecutive isolates. 87 
 88 
Identification and susceptibility testing 89 
Isolates were re-identified at AMRHAI as follows: S. aureus with Chromagar Staph aureus 90 
(Chromagar, Paris, France) and PCR for mecA;7 -haemolytic streptococci by Lancefield 91 
typing using Streptococcal Grouping Latex Kits (Pro-Lab Diagnostics, Merseyside, UK); 92 
enterococci and gram-negative bacilli by MALDI-ToF mass spectrometry (MALDI Biotyper, 93 
Bruker, Coventry, UK).  MICs were determined by BSAC agar dilution on IsoSensitest agar 94 
(Oxoid-Thermofisher, Basingstoke, UK),8 except that Isotonic agar with 50 mg/L Ca2+(Mast 95 
Laboratories, Bootle, UK) was used for daptomycin. Results were graded vs. EUCAST 96 
breakpoints (http://www.eucast.org), which have been adopted by the BSAC.9 Ceftaroline 97 
MICs additionally were determined by CLSI agar dilution10 on Mueller Hinton agar (Oxoid).   98 
Enterobacteriaceae found non-susceptible to ceftaroline (MIC >0.5 mg/L) and/or cefotaxime 99 
(MIC >1 mg/L) were subjected to ESBL tests, using BSAC agar dilution methodology to seek 100 
synergy between clavulanate 4 mg/L and cefepime, cefotaxime, ceftaroline or ceftazidime. 101 
 Antibiotic powders were obtained from suppliers as follows: ceftaroline (AstraZeneca, 102 
Macclesfield, UK), clavulanate (GlaxoSmithKline, Brentwood, UK) daptomycin (Novartis, 103 
Basel, Switzerland), linezolid and tigecycline (Pfizer, Sandwich, UK), cefepime (USP, 104 
Rockville, USA); quinupristin and dalfopristin (Nordic Pharma, Theale, UK); ampicillin, 105 
benzylpenicillin, cefotaxime, ceftazidime, ciprofloxacin, clindamycin, erythromycin, 106 
gentamicin, oxacillin, tetracycline, teicoplanin, vancomycin (Sigma, Poole, UK). 107 
  108 
Typing of S. aureus 109 
MRSA with ceftaroline MICs >2 mg/L were spa-typed as described by Harmsen et al.11 with 110 
types assigned via the Ridom GmbH spa website, http://www.spaserver.ridom.de. Multi 111 
Locus Sequence Type Clonal Complex (MLST-CC) assignments were inferred using the spa 112 
server (http://spa.ridom.de/mlst.shtml) and MLST database (http://saureus.mlst.net). 113 
 114 
Results 115 
The 35 laboratories contributed 11-60 isolates each, with a mean of 50 isolates/site and a 116 
total of 1908 consecutive organisms received. These were from 1756 patients: 1538 (87.4%) 117 
with a single pathogen and 219 (12.6%) with two or more pathogens; the latter total includes 118 
patients noted as co-infected with anaerobes, although these were not collected.  We also 119 
received 329 supplementary MRSA. As these lacked denominator data, they were used only 120 
to add robustness to MIC distributions, and were excluded from epidemiological analyses. 121 
 122 
Patient demographics and infection types 123 
The 1756 source patients for the consecutive isolates comprised 918 men and 838 women; 124 
35 aged 18-20 years; 131 from 21-30 years; 152 from 31-40 years; 189 from 41-50 years; 125 
224 from 51-60 years; 281 from 61-70 years; 327 from 71-80 years; 308 from 81-90 years 126 
and 109 aged 91 years or older.  Patients with MRSA averaged 5 years older (66.1 years, 127 
SD 19.9 years) than those with MSSA (61.4 years, SD 21.7 years).  Referring specialities 128 
(Table 1) were dominated by General Medicine and General Surgery, each accounting for 129 
around one quarter of patients. Accident and Emergency/Admissions Unit, Care of the 130 
Elderly, and Orthopaedic Surgery accounted for a further 7.6-15.2% of patients.  Only 4.4% 131 
of patients were in intensive care.  Patients’ infection types are summarised in Table 2: 132 
46.4% had surgical, traumatic or other wounds, whilst 16% had ulcers or sores and 11.3% 133 
had abscess infections.  Among smaller groups, 3.8% of patients had infected burns whilst 134 
4.4% had diabetes-related lower extremity infections.  Swabs were the dominant specimen 135 
type, from 1617/1756 (92%) patients; other samples included pus (n= 73), tissue (n=36), fine 136 
needle aspirates (n=14) and catheter tips (n=10). 137 
 138 
Pathogens in relation of hospital site and infection type 139 
S. aureus dominated, being present in 72.4% of infections sampled and the sole pathogen in 140 
64.7%.   It was present in 60-100% of infections in each hospitalisation category and each 141 
infection site (Tables 1 and 2); and was the sole pathogen in >57% infections at each 142 
infection site and in all settings except intensive care (47%). Fully 944/1756 (53.8%) of 143 
patients had infections solely involving MSSA. MRSA accounted for 15.8% of S. aureus, with 144 
proportions exceeding 20% in General Medicine, Neurology and Nephrology/Renal patients 145 
and among S. aureus isolates from infected lines, infected sores and ‘other’ wounds.  No 146 
MRSA were recovered from Haematology/Oncology or (unsurprisingly) Obstetrics-147 
Gynaecology patients and proportions were below 10% among S. aureus from Burns Units 148 
and burn infections, General Surgery and surgical site infection.  The MRSA rate among S. 149 
aureus isolates from General Medicine Patients (22.8%) was 2.5x that (9.3%) among 150 
General Surgery patients, with this excess substantially reflecting large numbers of MRSA 151 
from traumatic wounds and infected ulcers and sores – groups where the MRSA proportion 152 
exceeded 20%.  There was little major clustering when hospital site and infection type were 153 
combined (Table 3), but it is notable that more than half the General Medicine MRSA were 154 
from ulcers and ‘other (i.e. non-surgical) traumatic wounds.  MRSA proportions among S. 155 
aureus varied greatly with the hospital, from 0-68%: 10 sites had rates below 10%; 15 had 156 
rates 10-20%, five had rates 20-30% and five had rates >30%.  These last five, two of them 157 
in Wales, accounted for 72/201 of the MRSA collected (36%). Their distribution of clinical 158 
and ward/unit sites for MRSA resembled the generality of hospitals (now shown), suggesting 159 
that these excesses did not reflect different sampling approaches.  Among the 201 MRSA 160 
patients, 192 had MRSA as the sole pathogen and only nine had MRSA in mixed infections, 161 
three with P. aeruginosa and three with ‘unknown’ pathogens. 162 
 No other pathogen group besides S. aureus was recovered from more than 15% of 163 
all patients.  Enterobacteriaceae (n=269) included 125 E. coli, 38 Enterobacter spp., 34 164 
Proteus mirabilis and 34 Klebsiella/Raoultella spp., 14 Serratia spp. 13 Citrobacter spp. and 165 
11 indole-positive Proteeae, and were recovered from 252 patients (14.4%, with 17 having 166 
multiple species). In 179/252 cases (70.1%), Enterobacteriaceae were the sole pathogens; 167 
in the remainder they were co-present with other pathogens, predominantly S. aureus. 168 
Enterobacteriaceae were most frequent in General and Orthopaedic Surgery and Intensive 169 
Care Patients, being present in over 20% of surgical site infections, abscesses and (more 170 
surprisingly) line infections, but in fewer than10% of traumatic wound infections, infected 171 
ulcers, infected burns and infected dermatological conditions.  172 
 Streptococci were submitted from 9.3% of patients; most were Lancefield B, C, G 173 
organisms (n=137) not S. pyogenes (n=26). Prevalence was greatest in Accident and 174 
Emergency/Admissions Unit and Care of the Elderly patients and from infected ulcers and 175 
sores, cellulitis, infected dermatological conditions and diabetic lower extremity infections. 176 
Fewer than half (65/137) of the B, C, G streptococci were from monomicrobial infections 177 
versus two-thirds (17/26) of the S. pyogenes isolates.    178 
 P. aeruginosa was recovered from 138 patients (7.9%) and was sole pathogen in 179 
102.  Rates were highest in ICU, renal, cardiothoracic surgery and haematology/oncology 180 
patients, whereas the prevalence rate in Burns Unit (4.2%) and burn infections (6.1%) were 181 
low, despite the organism’s predilection for this milieu.12  Settings where P. aeruginosa was 182 
submitted from over 10% of cases included line infections, ‘other’ wound infections, diabetic 183 
lower extremity infections and cellulitis.    Enterococci (30 E. faecalis, 16 E. faecium and one 184 
E. raffinosus) were submitted from 37 (2.7%) of patients and were sole pathogens in 27.  185 
Proportions of patients with enterococci were highest (6.1-8.3%) in burn infections and Burns 186 
Units; settings with the highest rates were unrelated to those with the highest 187 
Enterobacteriaceae rates, despite both being gut organisms with the same likely origin. 188 
 189 
Antibiotic susceptibility 190 
Susceptibility data are summarised by species group in Tables 4-6 with ceftaroline MIC 191 
distributions shown in Table 7.  MSSA -accounting for 56.1% of all isolates- were very 192 
susceptible, with even erythromycin and tetracycline active vs. >85% of isolates (Table 4).  193 
MRSA were mostly resistant to erythromycin and ciprofloxacin but were otherwise 194 
susceptible, as typical of the EMRSA-15/CC22 and EMRSA-16/CC30 MRSA lineages 195 
predominant in the UK.13  Daptomycin, linezolid, tigecycline and glycopeptides were active 196 
against >99% of both MRSA and MSSA. Ceftaroline, 1 mg/L was active against all MSSA 197 
irrespective of method, and against 97.5% of the MRSA by BSAC methodology or 94.0% by 198 
CLSI methodology. These latter proportions trivially altered to 98.0% and 95.1%, 199 
respectively, when the supplementary MRSA were included (Table 7).  MICs for all the 200 
ceftaroline non-susceptible MRSA were 2 mg/L, representing the upper tail of a unimodal 201 
distribution, and counting as resistant by EUCAST criteria, though intermediate on those of 202 
the CLSI and FDA.  The 25 MRSA with MICs of 2 mg/L by CLSI methodology included all 203 
eight with MICs 2 mg/L by the BSAC method.  Twenty-three were spa-typed and all except 204 
one belonged to types corresponding to EMRSA-15/CC22 (n=10, spa types t022, t023, t032, 205 
t906, t747, t1977 and t3213) or EMRSA-16/CC30 (n=12, spa types t012, t018, t253); the 206 
exception was a CC5 spa t045 isolate.  207 
 All streptococci were susceptible to penicillin, ceftaroline, daptomycin, linezolid, 208 
tigecycline and glycopeptides (Table 4). Resistance was only frequent to tetracycline 209 
(especially for Group B /Streptococcus agalactiae) and erythromycin. MICs of ceftaroline 210 
were tightly clustered and unimodal, with values from 0.002-0.015 mg/L (Table 7).  Within 211 
this range, values were highest for Group B / S. agalactiae and lowest for S. pyogenes.   212 
Among enterococci (Table 5), 50% of E. faecalis and 33.3% of E. faecium had high-level 213 
gentamicin resistance and half the E. faecium isolates had glycopeptide resistance, always 214 
corresponding to the VanA phenotype, with both vancomycin and teicoplanin compromised.  215 
These high rates must be set against the overall infrequency of enterococci, which 216 
comprised less than 2% of the collection. With one exception (MIC, 4 mg/L) E. faecium 217 
isolates were highly resistant to ceftaroline but 25/30 E. faecalis were inhibited at 0.25-1 218 
mg/L, with MICs of 4-8 mg/L for the remaining five.   Bimodal MIC distributions were noted 219 
previously for E. faecalis with anti-MRSA cephalosporins, but remain unexplained.14 220 
 E. coli comprised almost half the Enterobacteriaceae collected (125/269, 46.4%), 221 
with Enterobacter spp., Klebsiella spp. and P. mirabilis each comprising 12.5-14.1%. Most of 222 
the resistance seen was of types inherent to particular species or genera (Table 6). Thus 223 
Klebsiella, Enterobacter, Citrobacter, Serratia and indole-positive Proteeae mostly were 224 
resistant to ampicillin Citrobacter freundii, Enterobacter, Serratia and Morganella morganii to 225 
co-amoxiclav. Over 85% of isolates of each species were susceptible to gentamicin and 226 
ciprofloxacin.  The behaviour of cephalosporins was more complex, and was investigated for 227 
all 45 isolates with ceftaroline MICs >0.5 mg/L.  These divided into three groups (Table 8). 228 
The first comprised 15 isolates – mostly E. coli and K. pneumoniae – deduced to have 229 
ESBLs based on synergy between all cephalosporins and clavulanate. These were all were 230 
substantially resistant to ceftaroline, with MICs >16 mg/L and to cefotaxime; many were also 231 
multiresistant to gentamicin and cirprofloxacin. The second group comprised 16 isolates –232 
mostly Enterobacter, C. freundii, M. morganii and Serratia – with greater resistance to 233 
cefotaxime, ceftazidime and ceftaroline than to cefepime, to which 13/16 remained 234 
susceptible. Cephalosporin MICs for these isolates were not reduced by clavulanate.  This 235 
combination of cefepime susceptibility and clavulanate-independent resistance implied high-236 
level AmpC activity.  MICs of ceftaroline for these isolates ranged from 2->256 mg/L with 237 
13/16 values >8 mg/L. The final group of 14 isolates had low-level ceftaroline resistance 238 
(MIC 1-16 mg/L) and were susceptible to the other three cephalosporins or had only 239 
intermediate resistance, with MICs never exceeding 2 mg/L: six were E. coli and six were 240 
Serratia spp.; ceftaroline MICs for the E. coli isolates were reduced by clavulanate to <0.12 241 
mg/L; those for the Serratia spp. were raised by clavulanate in many cases, implying AmpC 242 
induction. Overall, ceftaroline retained activity vs. 83.3% of Enterobacteriaceae isolates, with 243 
over 80% susceptibility except among Enterobacter (68.4%) and Serratia spp. (35.4%).  No 244 
Enterobacteriaceae were non-susceptible to cefotaxime but susceptible to ceftaroline. 245 
 For P. aeruginosa, susceptibility rates to ceftazidime, gentamicin and ciprofloxacin all 246 
exceeded 90%, confirming the pattern of infrequent resistance outside chronic respiratory 247 
infections that is typically seen in the UK.    248 
 249 
Ceftaroline MICs by BSAC vs CLSI methodology 250 
Ceftaroline MICs of 2 mg/L were found for a greater, but still small, proportion of MRSA by 251 
CLSI methodology than by BSAC methodology (Table 7).  This followed a wider pattern 252 
whereby, in >97% of cases excluding P. aeruginosa, MICs of ceftaroline by CLSI 253 
methodology on equalled those on IsoSensitest agar, or were two-fold higher (Table 9).  For 254 
P. aeruginosa the differential was 4-16-fold; reasons are unclear and the point is academic, 255 
since the species is universally agreed to be resistant, with no breakpoints assigned. 256 
 257 
Discussion 258 
We sought to define the current aetiology of SSSIs in the UK, the residual prevalence of 259 
MRSA, and the activity of ceftaroline.  The study aimed to provide a large snapshot, but two 260 
caveats should be noted: (i)  recording of ward type by participating laboratories is probably 261 
more accurate than recording of infection type, since laboratories know where a specimen 262 
has come from, but depend on the ward for information about the type of infection and (ii)  263 
we depended on laboratories’ categorisation of organisms as pathogens.  The proportion of 264 
SSSIs categorised as polymicrobial (12.6%) was lower than found by others – e.g. 41.4% in 265 
a 134-hospital, 12,506-patient US survey3 and 22.8% in Phase III trials with ceftaroline.15  266 
This may reflect differing ‘norms’ in recording secondary organisms, also our exclusion of 267 
coagulase-negative staphylococci, which were included as pathogens or co-pathogens in 268 
some surveys though not generally in Phase III SSSI data.   Despite these caveats, the unit 269 
and clinical site analyses presented in Tables 1 and 2 are mutually consistent with similar 270 
aetiology across e.g.: (i) surgical site infections and the General and Orthopaedic Surgery 271 
groups, and between burn infections and Burns Unit patients.   272 
 The species distributions, with S. aureus dominating in all subsets agrees with that 273 
reported by Lipsky et al.3 though percentages differ partly because Lipsky et al. accepted 274 
CoNS as significant, to the extent of including them as the sole pathogens in 18.2% of 275 
infections.  S. aureus was sole pathogen in 54.7% of Lipsky’s monomicrobial SSSIs, rising to 276 
66.8% if CoNS were discounted, compared with 64.7% here.  Proportions of monomicrobial 277 
infections with Enterobacteriaceae, streptococci (pooled), P. aeruginosa and enterococci 278 
were 10.1%, 9.5%, 3.1% and 3.5%, respectively, in Lipsky’s series, rising to 12.3%, 11.6%, 279 
3.8% and 4.3% once CoNS were disregarded, compared with 10.1%, 4.7%, 5.8, 1.5% here.  280 
Another study of 527 patients with healthcare-associated cSSSI,16 found S. aureus in 48.6%, 281 
enterococci in 14.6% and P. aeruginosa in 10.1%, whilst the SENTRY surveillance found 282 
that S. aureus accounted for 45.9% of SSSI pathogens and P. aeruginosa for 10.8%.17 283 
Recent Phase III antibiotic trials in complicated SSSI/ABSSSI trials18,19 again show a similar 284 
distribution, with S. aureus in more than half the patients and with -haemolytic streptococci, 285 
P. aeruginosa and Enterobacteriaceae in 5-20% each versus enterococci in under 5%.  The 286 
one radically different report is Public Health England’s surgical site surveillance for English 287 
hospitals 2013-4,20 which indicates a much lower proportion of S. aureus (16% or 18.4%, if 288 
rebased to exclude CoNS), with Enterobacteriaceae dominant (26%, or 30% if rebased to 289 
exclude CoNS).  The dominance of Enterobacteriaceae derived from their high proportion 290 
(56.7%) in infection following bowel surgery, where only 13.0% of patients had S. aureus. S. 291 
aureus remained the major pathogen in the PHE orthopaedic surgery series, present in 292 
54.5%-64.3% of monomicrobial infections.  The difference between the low rate of S. aureus 293 
in the PHE bowel surgery series and the high rate in the present General Surgery group 294 
(which should heavily represent bowel surgery) remains unexplained.  295 
 Asides from underscoring the dominance of S. aureus, the present analysis 296 
importantly shows: (i) that SSSIs in ICUs had a more diverse aetiology than those in other 297 
patient groups, with Enterobacteriaceae and P. aeruginosa more prevalent; (ii) that 298 
Enterobacteriaceae were also prominent in General and Orthopaedic Surgery patients, and 299 
in their surgical site infections; (iii) that, more surprisingly, Enterobacteriaceae were 300 
prevalent in line infections and (iv) that streptococci, which were mostly B, C, G types, were 301 
most prevalent in Emergency and Admissions Unit patients and Care of the Elderly and in 302 
cellulitis, whereas Enterobacteriaceae were rare pathogens in Emergency and Admissions 303 
Unit SSSI patients and Care of the Elderly. Such data, together with information on MRSA 304 
prevalence, point to settings where broad-spectrum therapy may be desirable in the 305 
empirical management of SSSIs.  Ceftaroline may have a particular potential in mixed SSSIs 306 
that involve MRSA together with Enterobacteriaceae, but these are now rare in the UK: only 307 
9/201 MRSA were from mixed infections and these largely had ‘unknowns’ or P. aeruginosa 308 
as the second isolate, not Enterobacteriaceae. 309 
  Rates of resistance were low.  Fully 944/1756 patients had monomicrobial MSSA 310 
infections.  Only 15.8% of S. aureus isolates were MRSA and among General Surgery 311 
patients, the MRSA rate was <10%.  This contrasts with a 61% MRSA rate among S. aureus 312 
from surgical site infections in England in 1997-921 and doubtless reflects the success of 313 
subsequent MRSA reduction programmes, which have also seen a >85% reduction in 314 
MRSA bacteraemias in England since their 2003/4 peak.22,23 Other settings where MRSA 315 
rates were below 10% included Burns Units, Obstetrics and Gynaecology and Haematology-316 
Oncology; an ICU MRSA rate of only 12.5% contrasts with 51.2% among SSSI ICU S. 317 
aureus in 200124.  The higher MRSA rate in General Medicine –two and a half times that in 318 
General Surgery– was associated with infected ulcers and ‘Other’ traumatic wounds (Table 319 
3).    The proportion of MRSA was higher particular hospitals, with 5/35 hospitals accounting 320 
for 35% of MRSA.  Two of these five sites were in Wales, which had risk-based pre-321 
admission MRSA screening during the survey period than universal screening, as then 322 
applied in England   Among other common pathogens, streptococci were universally 323 
susceptible, except to tetracycline and erythromycin whilst over 90% of Enterobacteriaceae 324 
were susceptible to ciprofloxacin and gentamicin and over 80% were susceptible to 325 
cephalosporins.  Over 90% of P. aeruginosa were susceptible to ciprofloxacin, gentamicin 326 
and ceftazidime.  327 
 Fully 97.5% (98.3% with supplementary isolates) of collected MRSA were 328 
susceptible to ceftaroline by BSAC methodology, with this proportion falling to 94.0% 329 
(95.1%) by CLSI methodology.  Typing found little exceptional about the resistant isolates, 330 
which almost all belonged to the EMRSA-15/CC22 and EMRSA-16/CC30 lineages that have 331 
long dominated among HA-MRSA in the UK.3,25  MICs never exceeded 2 mg/L, whereas 332 
values of 4 mg/L have been seen for small minorities of isolates in Greece and Germany, 333 
with some of these being shown to harbour PBP2’ mutations.26,27 Predictably, ceftaroline 334 
lacked activity against Enterobacteriaceae that were resistant to cefotaxime and which had 335 
profiles indicating ESBLs or derepressed AmpC. Resistance was seen also in a few further 336 
Enterobacteriaceae that lacked clear resistance to other cephalosporins; these 337 
predominantly comprised E. coli with ceftaroline/clavulanate synergy and Serratia spp. with 338 
ceftaroline MICS of 1 mg/L; the former group is in keeping with the observation that high-339 
level expression of classical TEM enzymes confers low-level protection against ceftaroline,14 340 
the second simply reflects Serratia spp. being inherently less susceptible than other 341 
Enterobacteriaceae (mode MIC 1 mg/L vs. 0.12-0.25 mg/L for other genera, Table 6), with 342 
the tail of the normal distribution thus being cut by the breakpoint.  343 
 In summary, these data provide a snapshot of the aetiology of SSSIs in the UK, 344 
indicating the dominance of MSSA and the settings where MRSA is now concentrated. In 345 
most cases, multiple treatment options remain and narrow-spectrum anti-gram-positive 346 
therapy is appropriate. Ceftaroline offers potential in the now less common situation where 347 
combinations of MRSA and Enterobacteriaceae are present.  348 
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/NR Derm Neuro 
Over-
all % 
S. aureus 75.1 64.6 80.8 81.2 67.9 51.3 65.0 85.4 71.0 75.9 62.1 83.3 100.0 83.3 72.4 
-Streptococci, A,B,C,G 9.1 8.7 16.1 13.3 4.5 3.8 6.7 6.3 9.7 0.0 0.0 4.2 0.0 8.3 9.3 
S. pyogenes 1.4 1.1 1.9 1.8 1.5 1.3 0.0 2.1 3.2 0.0 0.0 0.0 0.0 0.0 1.4 
Enterococci 0.9 3.4 1.9 1.8 3.0 6.4 5.0 8.3 3.2 0.0 7.1 4.2 0.0 8.3 2.7 
Enterobacteriaceae 11.0 24.1 4.6 6.1 20.1 30.8 15.0 6.3 16.1 13.8 10.3 8.3 0.0 0.0 14.4 
P. aeruginosa 9.1 6.7 6.5 6.7 7.5 16.7 11.7 4.2 3.2 10.3 13.8 4.2 0.0 8.3 7.9 
                
1 pathogen 88.8 85.1 84.7 87.3 94.8 79.5 85.0 91.7 96.8 100.0 93.1 91.7 92.3 83.3 87.6 
>1 pathogen 11.2 14.9 15.3 12.7 5.2 20.5 15.0 8.3 3.2 0.0 3.4 8.3 7.7 16.7 12.4 
S. aureus only 67.1 57.7 68.2 70.3 64.9 47.4 58.3 79.2 67.7 75.9 62.1 75.0 92.3 75.0 64.7 
                
MRSA as % S. aureus 22.8 9.3 14.7 18.7 19.8 12.5 15.4 4.9 0.0 0.0 22.2 25.0 15.4 20.0 15.8 
Total patients included 438 435 261 165 134 78 60 48 31 29 28 24 13 12 1756 
 
Abbreviations A&E Adm, Accident and Emergency/Admissions Unit; Burns, Burns Unit; CTS, Cardiothoracic Surgery; CoE, Care of Elderly; Derm, Dermatology; Gen Med, 
General medicine; Gen Surg, General Surgery; Haem Onc, Haematology/Oncology; ICU, Intensive Care Unit; Neph/Renal, Nephrology or Renal Unit; Neuro, Neurology; OB-








Table 2.  Pathogen distribution in relation to type of SSSI 
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S. aureus 60.9 82.1 77.5 67.3 75.8 76.8 66.7 84.8 81.5 61.7 75.7 92.6 72.4 
-Streptococci, A,B,C,G 4.8 8.8 16.8 9.5 11.4 14.7 14.1 4.5 3.7 0.0 8.1 18.5 9.3 
S. pyogenes 0.5 1.3 1.2 3.5 2.0 2.1 3.8 1.5 0.0 0.0 0.0 3.7 1.5 
Enterococci 3.9 1.0 0.8 4.5 0.7 2.1 5.1 6.1 3.7 3.3 5.4 0.0 2.7 
Enterobacteriaceae 27.5 6.5 4.9 20.6 8.7 10.5 14.1 4.5 5.6 20.0 13.5 3.7 14.4 
P. aeruginosa 8.9 5.9 8.2 3.5 8.1 11.6 11.5 6.1 11.1 15.0 8.1 3.7 7.9 
              
1 pathogen 89.3 92.5 83.6 86.9 89.3 78.9 84.6 87.9 85.2 90.0 83.8 77.8 87.6 
>1 pathogen 10.7 7.5 16.4 13.1 10.7 21.1 15.4 12.1 14.8 10.0 16.2 22.2 12.4 
S. aureus only 57.0 75.9 65.6 61.3 67.1 60.0 59.0 77.3 66.7 58.3 67.6 74.1 64.7 
              
MRSA as % S. aureus 9.3 19.4 17.5 17.2 16.8 12.3 15.4 7.1 29.5 21.6 25.0 12.0 15.8 
Grand total (n) 440 307 244 199 149 95 78 66 54 60 37 27 1756 
 482 
Abbreviations  Inf. Burn, infected burn; Inf derm cond, infected dermatological condition; Inf Sore, infected sore; Inf Ulcer, infected ulcer; Line inf, line 483 
infection; Other wound inf, other wound infection; NR, not reported; Surg site inf, surgical site infection; Traum. Wound inf, traumatic wound infection; 484 
Diab-related LE infection, diabetes related lower extremity infection485 
















/NR Over-all  
Abscess 7:24  0:3 1:3  6:24 5:46 0:1 1:2  1:1 0:2 2:4 0:1 23:111 
Cellulitis 2:21  2:4 0:7  4:17 1:6 0:1 0:1 0:1  0:1 3 0:2 9:64 
Infected burn 1 2:36  1:2  1:6 0:4 0:2 0:1      4:52 
Infected dermatological 
conditions 1:3   0:3 2:7 0:4 0:3 0:1      0:1 3:22 
Infected sore 2:3  0:1 0:1  3:7 0:4 0:1   0:1  1:3 1:0 7:21 
Infected ulcer 4:31 0:1 0:6 7:35 0:1 15:56 4:13  2:4 0:2  0:1 1:5 0:1 33:156 
Line infection 1:1  0:1   3:10 1:5 0:2 1:4 0:3 0:1 0:1 0:1 2:0 8:29 
Other wound 4:6  1:2 3:3  3:4 0:13  0:1    1:2 1:0 13:31 
Other/unknown 3:17 0:1 0:2 3:7 0:1 7:28 5:13 0:6 0:2 0:2 0:3 0:3 1:6 0:3 19:94 
Surgical site 2:21  1:11 1:8 0:2 4:26 6:102 0:4 0:15 1:4 1:1 0:12 9:34 0:3 25:243 
Traumatic wound 
infection 4:41 0:1 2:2 7:30  25:63 4:36 0:3 1:4 3:2 0:1 0:2 2:14 1:4 49:203 
Vascular diabetes related 
lower extremity infection 1:11  0:1 2:10  4:9 0:10 0:1 0:1    1:1  8:44 
(blank)                
Grand Total 31:180 2:39 6:33 25:109 2:11 75:254 26:255 0:22 5:35 4:14 2:8 0:22 18:73 5:15 201:1070 
 488 
Numbers are in the format No. MRSA: No. MSSA; they are in bold wherever the total number of S. aureus was >20 and the proportion of MRSA was > 25%489 




























MSSA (1070) 100 100 91.7 (98.3)b 86.4 99.9 98.7 100 NT 93.1 99.7 100 99.9 
MRSA (201)a 94.1 97.6 20.6 (86.3)b 38.7 99.5 91.8 100 NT 87.5 99.8 100 100 
S. pyogenes (25) 100 100 No bpt 100 100 100 NT 100 100 80 100 100 100 
S. agalactiae (39) 100 100 No bpt (89.7)b 89.7 100 NT 100 100 12.8 100 100 100 
S. dysgalactiae (98) 100 100 No bpt (92.6)b 66.0 100 NT 100 100 41.8 98.0 100 100 
 492 
a Excludes supplementary MRSA – see Table 7  493 
Table 5.    Percent susceptibility among enterococci  494 
 495 
 Cefta- 























E. faecalis (30) No bpt No bpt 100 90%  
<1 mg/l 
50 0 100 10.0 100.0 96.7 96.7 
E. faecium (16) No bpt No bpt 0 All 2-4 mg/L 66.6 50 100 50.0 100.0 50.0 50.0 
 496 
Abbreviations as in Table 4 497 
a Percentage with only low level intrinsic resistance, MIC <128 mg/L  498 









Cefotaxime Gentamicin Ceftazidime 
Citrobacter (13) 84.6 84.6 (15.4) 69.2a 100 84.6 100 NT 
Enterobacter (38) 68.4 68.4 (23.7) (5.3) 97.3 68.4 92.1 NT 
E. coli (125) 89.6 89.6 38.4 73.6 88.0 94.4 91.2 NT 
Klebsiella/ Raoultella (34) 82.4 82.4 0 91.2 94.1 85.3 97.1 NT 
Indole-positive Proteeae (11) 81.8 81.8 0 36.3b 90.9 81.8 90.9 NT 
P. mirabilis (34) 94.1 97.1 79.4 97.1 94.1 97.1 94.1 NT 
Serratia (14)` 14.3 35.7 0 7.1 92.9 85.7 100 NT 
P. aeruginosa (138) No bpt No bpt NT NT 92.8  98.6 93.5 
 502 
Abbreviations as in Table 4 503 
a C. koseri susceptible; C. freundii and C. braakii resistant 504 







  512 
Table 7.  MIC distributions of ceftaroline for collected SSSI isolates 513 
 MIC (mg/L)  
 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 Total 
MSSA ISO    1 1 5 134 917 12           1070 
MRSA ISO       1 19 129 47 5         201 
         inc. suppla       1 48 315 159 8         530 
MSSA MH agar      6 44 1000 20           1070 
MRSA MH agar        6 64 119 12         201 
       inc. suppla         7 163 336 25         530 
S. pyogenes 1 24                  25 
Group B   1 38                39 
Group C,G  47 51                 98 
E. faecalis        2 19 4  2 3       30 
E. faecium            1     1  14 16 
                      
Citrobacter      5 5 1       1    1 13 
Enterobacter 
spp.      2 16 5 3  1  2 1 2 3 1 1 1 38 
Escherichia coli     4 41 41 14 12 2 1 2 1   1  1 5 125 
Indole  + ve 
Proteeae     2 4 2 1       1 1    11 
Klebsiella/ 
Raoultella      4 16 4 4 1    1    1 3 34 
Proteus mirabilis     8 18 3 3 1     1      34 
Serratia spp.        1 4 5 1 2 1       14 
                      
Acinetobacter 
spp.         1 1 2 1      1  6 
P. aeruginosa          1 65 43 17 2 1 3 4  2 138 
 514 
Table excludes all species groups with fewer than five isolates  515 
 516 
a Including also the additional 15 MRSA sought per site. 517 
 518 
Dark shading: Resistant based on EUCAST breakpoints 519 
 520 
Light shading: species with no breakpoints 521 
 522 
 523 
  524 








E. coli 7  6 
Klebsiella / Raoultella spp. 5  1 
Enterobacter spp. 3 9  
Citrobacter spp.  2  
P. mirabilis   1 
Indole-positive Proteeae  2  
Serratia spp.  3 6 
Cefotaxime-susceptible 0 1 13 
Ceftazidime-susceptible 1 3 13 
Cefepime-susceptible 2 13 14 
Ceftaroline MICs (mg/L)a 16->256 2->256 1-8 
Ceftaroline/clav MICs (mg/L)a 0.06-0.25 8->64 0.06-16b 
 526 
a Based on results on IsoSensitest agar 527 
b Low values are for E. coli, where ceftaroline/clavulanate synergy was observed; high values for Serratia, often with antagonism of 528 
 ceftaroline by clavulanate 529 
 530 
531 
Table 9.  Ratios of MICs by CLSI methodology on Mueller-Hinton agar : MICs by BSAC methodology on IsoSensitest agar for ceftaroline 532 
 No. isolates with indicated MIC ratio 
 0.25 0.5 1 2 4 8 16 32 
B,C,G strep 2 2 95 38     
Enterobacteriaceae  15 160 88 5 1   
Enterococci   24 23     
MRSA  1 99 100 1    
MSSA  7 952 110 1    
Others  1 6 4 2   1 
P. aeruginosa   6 13 37 47 32 3 




  536 
 537 
 538 
